Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PBP1510

Monoclonal antibody · Antagonist of PAUF · developed by Prestige Biopharma

Phase 1/2 Most advanced trial

PBH Developer

1 Registered trials

What is PBP1510?

PBP1510 is a humanized IgG1 monoclonal antibody that targets and neutralizes PAUF. It is being studied in pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: PAUF
Mechanism: Antagonist of PAUF
Therapy area: Oncology
Developer: Prestige Biopharma Limited (PBH)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: HX998WER5A

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05141149	Phase 1/2	Pancreatic Cancer	Active not recruiting	PBH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Cancer

Sources

ClinicalTrials.gov NCT05141149

Updated Oct 3, 2026. Something wrong or missing? Report it on the PBH page.

Follow PBH, the company behind PBP1510

See PBH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PBH catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z